TY - JOUR
T1 - Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation
AU - Jamasbi, Janina
AU - Megens, Remco T. A.
AU - Bianchini, Mariaelvy
AU - Uhland, Kerstin
AU - Münch, Götz
AU - Ungerer, Martin
AU - Sherman, Shachar
AU - Faussner, Alexander
AU - Brandl, Richard
AU - John, Christine
AU - Buchner, Johannes
AU - Weber, C.
AU - Lorenz, Reinhard
AU - Elia, Natalie
AU - Siess, Wolfgang
PY - 2016
Y1 - 2016
N2 - To enhance the antithrombotic properties of recombinant glycoprotein VI fragment crystallizable (GPVI-Fc), the authors incubated GPVI-Fc with anti-human Fc antibodies to cross-link the Fc tails of GPVI-Fc. Cross-linking potentiated the inhibition of human plaque- and collagen-induced platelet aggregation by GPVI-Fc under static and flow conditions without increasing bleeding time in?vitro. Cross-linking with anti-human-Fc Fab2 was even superior to anti-human-Fc immunoglobulin G (IgG). Advanced optical imaging revealed a continuous sheath-like coverage of collagen fibers by cross-linked GPVI-Fc complexes. Cross-linking of GPVI into oligomeric complexes provides a new, highly effective, and probably safe antithrombotic treatment as it suppresses platelet GPVI-plaque interaction selectively at the site of acute atherothrombosis.
AB - To enhance the antithrombotic properties of recombinant glycoprotein VI fragment crystallizable (GPVI-Fc), the authors incubated GPVI-Fc with anti-human Fc antibodies to cross-link the Fc tails of GPVI-Fc. Cross-linking potentiated the inhibition of human plaque- and collagen-induced platelet aggregation by GPVI-Fc under static and flow conditions without increasing bleeding time in?vitro. Cross-linking with anti-human-Fc Fab2 was even superior to anti-human-Fc immunoglobulin G (IgG). Advanced optical imaging revealed a continuous sheath-like coverage of collagen fibers by cross-linked GPVI-Fc complexes. Cross-linking of GPVI into oligomeric complexes provides a new, highly effective, and probably safe antithrombotic treatment as it suppresses platelet GPVI-plaque interaction selectively at the site of acute atherothrombosis.
U2 - 10.1016/j.jacbts.2016.03.008
DO - 10.1016/j.jacbts.2016.03.008
M3 - Article
C2 - 27766315
SN - 2452-302X
VL - 1
SP - 131
EP - 142
JO - JACC: Basic to Translational Science
JF - JACC: Basic to Translational Science
IS - 3
ER -